Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae-Reference-Cited by-同舟云学术

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae

Published:2020-02-21 Issue:3 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ji Xi-wei¹,Xue Feng¹,Kang Zi-sheng¹,Zhong Wei¹,Kuan Isabelle Hui-san²,Yang Xi-ping³,Zhu Xiao²,Li Yun¹,Lv Yuan¹^ORCID

Affiliation:

1. Institute of Clinical Pharmacology, Peking University First Hospital, Beijing, China

2. School of Pharmacy, University of Otago, Dunedin, New Zealand

3. XuanZhu Pharma Co., Ltd., Jinan, Shandong, China

Abstract

Benapenem is a novel carbapenem. The objective of this study was to determine the pharmacokinetic (PK)/pharmacodynamic (PD) cutoff values and evaluate the optimal administration regimens of benapenem for the treatment of bacterial infections via PK/PD modeling and simulation. Ertapenem was used as a control. Infected mice received an intravenous (i.v.) injection of benapenem or ertapenem of 14.6, 58.4, or 233.6 mg/kg of body weight, and the PK/PD profiles were evaluated.

Funder

National Natural Science Foundation of China

MOST | National Major Science and Technology Projects of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01751-19

Reference36 articles.

1. Pharmacodynamic evaluation of benapenem, a new carbapenem antibiotic, in mouse urinary tract infection model;Lu X;Chin Med Biotechnol,2015

2. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation